Polypid To Participate In The Craig-Hallum 15Th Annual Alpha Select Conference
Date
11/7/2024 7:17:02 AM
(MENAFN- GlobeNewsWire - Nasdaq) PETACH TIKVA, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the“Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company's management will participate in investor meetings at the Craig-Hallum 15th Annual Alpha Select conference on November 19, 2024, in New York, NY.
Investors interested in meeting with PolyPid should contact the conference representative directly.
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD ) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid's lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.
For additional Company information, please visit and follow us on Twitter and LinkedIn .
Contacts:
PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
...
Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
...
MENAFN07112024004107003653ID1108861082
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.